BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Related Posts
19Aug
Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition 2020
PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more
12Nov
Privo Technologies receives $3M Bridge Award from the National Cancer Institute (NCI).
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
10Jan
Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more
22Oct
Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma
PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more
18Jun
BIO International Convention 2021
Privo Technologies, Inc. attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more
30Jun
Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more
01Aug
Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
01Jan
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more
07Sep
FDA Grants $2 million award to Privo Technologies to expedite its clinical trial
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more
12Aug
Privo Technologies, Inc. Receives 3rd U.S. FDA Orphan Drug Designation
Peabody, MA – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug... read more
- © UX Strategy & Digital Branding
